Re-administration of gefitinib following diffuse interstitial lung disease in a patient with advanced lung adenocarcinoma: A case report and review of the literature

Zhang,Xueli; Li,Huiqiao; Zhu,Min; Zhang,Yuhui

doi:10.3892/ol.2015.3026

May-2015 Volume 9 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

May-2015 Volume 9 Issue 5

Full Size Image

Case Report

Re-administration of gefitinib following diffuse interstitial lung disease in a patient with advanced lung adenocarcinoma: A case report and review of the literature

Authors:
- Xueli Zhang
- Huiqiao Li
- Min Zhu
- Yuhui Zhang
View Affiliations / Copyright

Affiliations: Beijing Institute of Respiratory Medicine, Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing Chao‑Yang Hospital, Capital Medical University, Beijing 100020, P.R. China
Pages: 2419-2421
|
Published online on: March 11, 2015

https://doi.org/10.3892/ol.2015.3026
Expand metrics +

Abstract

Interstitial lung disease (ILD) is a severe adverse effect of gefitinib treatment. Re‑administration of gefitinib to patients suspected of suffering from gefitinib‑induced ILD requires cautious consideration. In the majority of cases, gefitinib is not re‑administered to such patients. The present study reports a case of advanced lung adenocarcinoma, where the patient developed gefitinib‑induced ILD and gefitinib was re‑administered at 3.5 months after discontinuation of gefitinib treatment. Initially, the patient achieved partial clinical remission, but developed diffuse ILD following gefitinib administration for 5 months. Following the onset of ILD, gefitinib was discontinued immediately and low‑dose corticosteroids were administered at the early stages of ILD. Subsequent to recovery from the lung injury, gefitinib was re‑administered along with N‑acetylcysteine. The patient presented with good lung adenocarcinoma control and did not experience a recurrence of ILD for >16 months. Thus, early discontinuation and gefitinib re‑administration with N‑acetylcysteine may be a potential novel treatment strategy for gefitinib‑induced ILD.

View Figures

View References

1	Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 21:2237–2246. 2003. View Article : Google Scholar : PubMed/NCBI
2	Kris MG, Natale RB, Herbst RS, et al: Efficacy ofgefitinib, an inhibitor of the epidermal growth factor receptor tyrosinekinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 290:2149–2158. 2003. View Article : Google Scholar : PubMed/NCBI
3	Inoue A, Saijo Y, Maemondo M, et al: Severe acute interstitialpneumonia and gefitinib. Lancet. 361:137–139. 2003. View Article : Google Scholar : PubMed/NCBI
4	Okamoto I, Fujii K, Matsumoto M, et al: Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer. Lung Cancer. 40:339–342. 2003. View Article : Google Scholar : PubMed/NCBI
5	Ricciardi S, Tomao S and de Marinis F: Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer. 10:28–35. 2009. View Article : Google Scholar : PubMed/NCBI
6	Ando M, Okamoto I, Yamamoto N, et al: Predictive factors for interstitial lungdisease, antitumorresponse and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 24:2549–2556. 2006. View Article : Google Scholar : PubMed/NCBI
7	Luo C, Lv M, Li Y, et al: Gefitinib-induced interstitial pneumonia: A casereport and review of the literature. Exp Ther Med. 7:855–859. 2014.PubMed/NCBI
8	Suzuki M, Asahina H, Konishi J, Yamazaki K and Nishimura M: Recurrent gefitinib-induced interstitial lung disease. Intern Med. 47:533–536. 2008. View Article : Google Scholar : PubMed/NCBI
9	Takamochi K, Suzuki K, Bashar AH, et al: Readministration of gefitinib in a responder after treatment discontinuation due to gefinitib-related interstitial lung disease: a case report. J Med Case Rep. 1:1382007. View Article : Google Scholar : PubMed/NCBI
10	Goto Y, Hojo M, Takeda Y, Kobayashi N and Kudo K: Gefitinib-induced interstitial lung disease-addition of intravenous cyclophosphamide to corticosteroids is a valuable treatment option: A case report. Med Oncol. 27:753–755. 2010. View Article : Google Scholar : PubMed/NCBI
11	Seto T, Seki N, Uematsu K, et al: Gefitinib-induced lung injury successfully treated with high-dose corticosteroids. Respirology. 11:113–116. 2006. View Article : Google Scholar : PubMed/NCBI
12	Kudoh S, Kato H, Nishiwaki Y, et al: Japan Thoracic Radiology Group: Interstitial lung disease in Japanese patients with lung cancer: acohort and nested case-control study. Am J Respir Crit Care Med. 177:1348–1357. 2008. View Article : Google Scholar : PubMed/NCBI
13	Kitajima H, Takahashi H, Harada K, et al: Gefitinib-induced interstitial lung disease showing improvement after cessation: disassociation of serummarkers. Respirology. 11:217–220. 2006. View Article : Google Scholar : PubMed/NCBI
14	Gillissen A: Anti-inflammatory efficacy of N-acetylcysteine and therapeutic usefulness. Pneumologie. 65:549–557. 2011.[In German]. View Article : Google Scholar : PubMed/NCBI
15	Albera C, Ferrero C, Rindone E, Zanotto S and Rizza E: Where do we stand with IPF treatment? Respir Res. 14(Suppl 1): S72013.PubMed/NCBI
16	Behr J and Richeldi L: Recommendations on treatment for IPF. Respir Res. 14(Suppl 1): S62013.PubMed/NCBI
17	Idiopathic Pulmonary Fibrosis Clinical Research Network, ; Raghu G, Anstrom KJ, King TE Jr..Lasky JA and Martinez FJ: Prednisone, azathioprine and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 366:1968–1977. 2012. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Re-administration of gefitinib following diffuse interstitial lung disease in a patient with advanced lung adenocarcinoma: A case report and review of the literature

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles